Company Filing History:
Years Active: 2003
Title: Shin'ichiro Oguni: Innovator in Erythroblast Diagnostic Methods
Introduction
Shin'ichiro Oguni is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the area of erythroblast analysis. His innovative work has led to the development of a patented method that enhances the accuracy and efficiency of diagnosing blood-related conditions.
Latest Patents
Oguni holds a patent for the "Erythroblast diagnostic flow-cytometry method and reagents." This invention provides a simple and rapid way to discriminate and count erythroblasts in peripheral blood or circulatory system-related samples. The method is characterized by its high precision and involves the use of a hemolytic agent that dissolves erythrocytes in a body fluid sample. This agent conditions leukocytes and erythroblasts to be suitable for staining. The reagents include at least one fluorescent dye that stains leukocytes and erythroblasts differentially. When mixed with the sample, a detectable difference in fluorescence intensity arises under laser illumination during flow cytometric analysis. Additionally, the reagents contain a surfactant that enables the discrimination of erythroblasts by their maturation stages.
Career Highlights
Shin'ichiro Oguni is associated with Sysmex Corporation, a company known for its advanced diagnostic and laboratory equipment. His work at Sysmex has been pivotal in advancing diagnostic methodologies in hematology. With a focus on precision and efficiency, Oguni's contributions have had a lasting impact on the field.
Collaborations
Oguni has collaborated with notable colleagues, including Tomohiro Tsuji and Takashi Sakata. Their combined expertise has further enhanced the development and application of innovative diagnostic methods.
Conclusion
Shin'ichiro Oguni's contributions to the field of erythroblast diagnostics exemplify the importance of innovation in medical technology. His patented methods and reagents represent a significant advancement in the accurate analysis of blood samples. The impact of his work continues to resonate within the medical community, improving diagnostic capabilities and patient outcomes.